Table 3.
NSPC-based clinical trials.
| Title | Start–End | Conditions | Intervention |
|---|---|---|---|
| Pilot Investigation of Stem Cells in Stroke | Jun. 2010–Mar. 2023 | Stroke | Biological: CTX0E03 neural stem cells |
| Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Patients With Thoracic Spinal Cord Injury | Mar. 2011–Apr. 2015 | Thoracic SCI | Biological: HuCNS-SC cells |
| Human Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis (ALS) (hNSCALS) | Dec. 2011–Dec. 2015 | Amyotrophic Lateral Sclerosis | Biological: Human Neural Stem Cells |
| Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD) | Jun. 2012–Jun. 2015 | Macular Degeneration | Drug: HuCNS-SC cells |
| Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis | Apr. 2014–Mar. 2017 | Multiple Sclerosis | Biological: intrathecal administration of autologous MSC-NP |
| Pilot Investigation of Stem Cells in Stroke Phase II Efficacy (PISCES-II) | Jun. 2014–16 Aug. 2017 | Ischaemic Stroke/Cerebral Infarction/Hemiparesis/Arm Paralysis | Biological: CTX DP |
| Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI (SCI) | Aug. 2014–Dec. 2022 | SCI | Drug: Human spinal cord stem cells. |
| NeuroRegen Scaffold™ Combined With Stem Cells for Chronic Spinal Cord Injury Repair | Jan. 2016–Dec. 2021 | SCI | Biological: NeuroRegen scaffold/neural stem cells transplantation |
| Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients (NSC-SPMS) | 9 Sept. 2017–29 May 2021 | Multiple Sclerosis | Biological: Human Neural Stem Cells |
| Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis | 21 Sept. 2018 –Nov. 2023 | Multiple Sclerosis | Biological: Intrathecal MSC-NP injection/Other: Intrathecal saline injection |
| Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson’s (PD). | Jun. 2018–Sept. 2020 | Parkinson Disease | Biological: Injection of Umbilical cord derived MSCs |
| CNS10-NPC for the Treatment of RP | Mar. 2020–Jun. 2022 | Retinitis Pigmentosa | Biological: CNS10-NPC implantation |
| A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS) | 4 Jan. 2021–31 Dec. 2024 | Ischemic Stroke | Biological: Neural Stem Cells |
| Transplantation of Neural Stem Cell-Derived Neurons for Parkinson’s Disease | Jun. 2021–30 Jun. 2023 | Parkinson’s Disease | Biological: Intracerebral microinjections |
Recruiting, current, and past NSPC-based clinical trials (retrieved from ClinicalTrials.gov, accessed on 14 July 2021).